-
-
-
-
-
-
-
Journey Medical secures third major GPO contract for Emrosi rosacea drug
-
-
-
-
-
-
-
UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
-
-
-
-
-
-
-
Journey Medical publishes Emrosi clinical trial results in dermatology journal
-
-
-
-
-
-
-
Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference
-
-
-
-
-
-
-
Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11
-
-
-
-
-
-
-
Journey Medical to Join Russell 2000® and Russell 3000® Indexes
-
-
-
-
-
-
-
Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
-
1,186,123 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

